Fulcrum Therapeutics FULC 深 沪
已收盘 08-21 16:00:00 美东时间
3.83
-0.020
-0.52%
华盛通- 最 高3.90
- 今 开3.85
- 成交量 151.26万股
- 最 低 3.78
- 昨 收 3.85
- 总市值 2.92亿
- 52周最高 15.7399
- 市盈率 静 --
- 换手率 1.98%
- 52周最低 2.83
- 委 比 -80.35%
- 总股本 7629.73万
- 历史最高 33.098
- 量 比 0.49
- 振 幅 3.12%
- 历史最低 2.25
- 每 手 1
- 风险率 2.70%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Fulcrum Therapeutics, Slate Medicines to merge in all-stock deal
Fulcrum Therapeutics (FULC) and Slate Medicines agreed to combine in an all-stock transaction, creating a company focused on developing next-generation migraine therapies. FULC shares jumped nearly +1...
08-17 19:15
Fulcrum Therapeutics and Slate Medicines Announce Merger Agreement to Advance Next-Generation Migraine Therapies
Fulcrum Therapeutics and Slate Medicines have agreed to merge in an all-stock transaction, with the combined company operating as Slate Medicines. The merger aims to advance Slate's pipeline of next-generation migraine therapeutics, including SLTE-1009, a clinical-stage anti-PACAP/VIP monoclonal antibody. Slate has secured $245 million in private placement financing, expected to fund operations into 2029. The transaction is subject to customary c...
08-17 11:00
Fulcrum Therapeutics Advances Restructuring with Leadership Changes
Fulcrum Therapeutics ( ($FULC) ) has provided an announcement. On May 31, 2026,...
06-12 06:21
What's Going On With Fulcrum Therapeutics Stock On Thursday?
Fulcrum Therapeutics halts pociredir development after FDA concerns over malignancy risk and begins a strategic review.
06-04 22:22
美股大行评级 | 潜在涨幅43%，慧与获11家大行集体上调目标价；最高300美元，Credo获9家大行集体上调目标价
今日重点评级关注：Ascendiant Capital：维持Genasys"买入"评级，目标价从5.5美元升至6美元；Citizens：维持Abivax"跑赢大市"评级，目标价从131美元升至187美元
06-03 11:17
Stifel Downgrades Fulcrum Therapeutics to Hold, Lowers Price Target to $3
Stifel analyst James Condulis downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Buy to Hold and lowers the price target from $25 to $3.
06-03 01:57
美国Fulcrum制药公司因安全风险终止多动症新药研发 股价暴跌逾五成并寻求转让
美国生物制药公司Fulcrum Therapeutics（股票代码：FULC.O）2日宣布，因美国食品和药物管理局（FDA）对潜在致癌风险提出严重关切，公司...
06-02 21:56
Fulcrum plunges after discontinuing lead program
Fulcrum Therapeutics (FULC) lost nearly 50% of its value in extended trading after the company disclosed plans to discontinue the development of its lead asset, pociredir, for sickle cell disease in r...
06-02 18:58
